Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

Dr. Kaori  Ouchi

Vice President & Head of Drug Safety Division

Ms. Satoko  Shisai

Executive Vice President & Head of Digital Transformation Unit

Dr. Tomoyuki  Igawa Ph.D.

Associate Vice President & Head of Translational Research Division

Mr. Nobuya  Ishii

Head of Science  & Technology Intelligence Dept., Project and Lifecycle Management Unit

Mr. Yoshiyuki  Yano

Executive Vice President

Toshiya  Sasai

Executive of Investor Relations Group & Corporate Communications Department

Dr. Osamu  Okuda

President, Chief Executive Officer & Representative Director

Mr. Shinji  Hidaka

Executive Vice President and Head of Marketing & Sales Division

Mr. Junichi  Ebihara

Mr. Tetsuya  Yamaguchi

Executive Vice President and Head of Project, Lifecycle Management & Foundation Medicine Unit

Chugai Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Co., Ltd. Management Structure

Management information